Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Increases in COVID, RSV, and influenza are the result of governments refusal to enact public health measures and address ...

Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it's true that fewer people get ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

The Ministry of Public Health’s latest epidemiological bulletin paints a stark picture of rising respiratory infections and a ...

In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse ...

The respiratory syncytial virus (RSV) vaccine, introduced across the UK in late summer 2024, led to a 72% reduction in babies hospitalised with the virus if mothers were vaccinated, a new study has ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...